Guizhou Bailing Group Pharmaceutical (002424.SZ): The clinical trial application for Tangning Tongluo Tablets has been approved.
Guizhou Bailin (002424.SZ) announcement, the company's wholly-owned subsidiary Bailin Yuxiu (Zhuhai) Pharmaceutical Co., Ltd.
Guizhou Bailing Group Pharmaceutical (002424.SZ) announced that its wholly-owned subsidiary, Bailin Yuxiu (Zhuhai) Pharmaceutical Co., Ltd. (referred to as "Bailin Yuxiu"), has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA). The application for the clinical trial of Tangning Tongluo Tablets submitted by Bailin Yuxiu has been approved, allowing the product to be used in clinical trials for type 2 diabetes.
Related Articles
Shenzhen Topway Video Communication (002238.SZ) Authorized to Organize the Safe Operation of State-Owned Assets and Enterprises Online Regulation (Shenzhen) Sub-center.
Riyue Heavy Industry (603218.SH) plans to reduce its holdings of up to 156,900 shares.
KN Hospital (02120) will distribute an interim dividend of HK$1.9714 for every 10 shares on November 21st.
Shenzhen Topway Video Communication (002238.SZ) Authorized to Organize the Safe Operation of State-Owned Assets and Enterprises Online Regulation (Shenzhen) Sub-center.
Riyue Heavy Industry (603218.SH) plans to reduce its holdings of up to 156,900 shares.
KN Hospital (02120) will distribute an interim dividend of HK$1.9714 for every 10 shares on November 21st.
